Lucy Scientific Discovery (Lucy Scientific Discovery) EBIT : $-8.53 Mil (TTM As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Lucy Scientific Discovery EBIT?

Lucy Scientific Discovery's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-1.18 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-8.53 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Lucy Scientific Discovery's annualized ROC % for the quarter that ended in Dec. 2023 was -72.53%. Lucy Scientific Discovery's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -571.78%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Lucy Scientific Discovery's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -241.08%.

Lucy Scientific Discovery EBIT Historical Data

The historical data trend for Lucy Scientific Discovery's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lucy Scientific Discovery EBIT Chart

Lucy Scientific Discovery Annual Data

Trend

Jun21

Jun22

Jun23

EBIT

-2.37

-3.79

-7.02

Lucy Scientific Discovery Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial						-0.18	-3.57	-2.18	-1.61	-1.18

Competitive Comparison of Lucy Scientific Discovery's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Lucy Scientific Discovery's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lucy Scientific Discovery's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lucy Scientific Discovery's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Lucy Scientific Discovery's EV-to-EBIT falls into.

Lucy Scientific Discovery EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.53 Mil.

Lucy Scientific Discovery (NAS:LSDI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Lucy Scientific Discovery's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-3.452 * ( 1 - 0% )	/	( (5.076	+	4.443)	/ 2 )
=	-3.452	/	4.7595
=	-72.53 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	6.266	-	1.827	-	( 0.238	-	max(0, 2.226	-	1.589	+	0.238	))
=	5.076

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4.287	-	1.993	-	( 0.211	-	max(0, 3.487	-	1.338	+	0.211	))
=	4.443

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Lucy Scientific Discovery's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-4.7	/	( ( (1.644 + max(-0.486, 0))	+	(0 + max(-0.874, 0)) )	/	2 )
=	-4.7	/	( ( 1.644	+	0 )	/	2 )
=	-4.7	/	0.822
=	-571.78 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.341)	-	(1.827	+	0	+	0)
=	-0.486

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.001	+	0	+	1.118)	-	(1.993	+	0	+	0)
=	-0.874

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Lucy Scientific Discovery's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-8.527	/	3.537
	=	-241.08 %

Lucy Scientific Discovery EBIT Related Terms

Thank you for viewing the detailed overview of Lucy Scientific Discovery's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Lucy Scientific Discovery (Lucy Scientific Discovery) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lucy Scientific Discovery Inc (NAS:LSDI) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

301-1321 Blanshard Street, Victoria, BC, CAN, V8W 0B6

Website

https://www.lucyscientific.com

Lucy Scientific Discovery Inc is an early-stage psychotropics contract manufacturing company focused on becoming the contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry. Its drug products are designed to treat a range of mental health and cognitive conditions.

Executives

Richard D Nanula	director, officer: Executive Chairman	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Charles B Nemeroff	director	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Paul Abramowitz	director	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Brian Zasitko	officer: Chief Financial Officer	C/O LUCY SCIENTIFIC DISCOVERY, INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Scott M. Reeves	director	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Christopher Mcelvany	director, officer: President and CEO	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Livio Susin	director	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Brittany Kaiser	director	C/O LUCY SCIENTIFIC DISCOVERY INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6
Assad J Kazeminy	officer: Chief Scientific Officer	C/O LUCY SCIENTIFIC, INC., 301-1321 BLANSHARD STREET, VICTORIA A1 V8W 0B6